Bioventus Inc.
BVS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BVS
Bioventus Inc. is a medical device company focused on surgical solutions, pain treatments, and restorative therapies, with a recent strategic review of alternatives and a strong financial position as of mid-2026.
Key risk: Strategic alternatives uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 27, 2026.
Tracking 1 clinical trial for Bioventus Inc..
Bioventus Inc. is a medical device company focused on surgical solutions, pain treatments, and restorative therapies, with a recent strategic review of alternatives and a strong financial position as of mid-2026.
- As of June 27, 2026, Bioventus reported cash & equivalents of $29.5M, total revenue of $153.2M, net income of $33.4M, shareholders' equity of $184.1M, and total debt of $27.0M [sec].
- The company delivered its third consecutive year of strong results in 2025, with disciplined operational execution and portfolio optimization [sec · filed 2026-04-22].
- Net sales from Pain Treatments increased $8.3M in Q2 2026, driven by 9.3% volume growth led by Durolane and 3.6% price growth [sec_mda · as of 2026-08-05].
- Bioventus entered into a $300.0M term loan and a $100.0M revolving credit facility in July 2025 to support liquidity and capital needs [sec_mda · as of 2026-05-06].
- The company is reviewing potential strategic alternatives, with outcomes and timing uncertain [sec · filed 2026-08-05].
What works
- Strong financial performance with net income of $33.4M and positive shareholders' equity of $184.1M as of June 27, 2026 [sec].
- Consistent revenue growth in Pain Treatments, particularly Durolane, with 9.3% volume growth in Q2 2026 [sec_mda · as of 2026-08-05].
- Access to significant liquidity through a $300.0M term loan and $100.0M revolving credit facility [sec_mda · as of 2026-05-06].
- Successful divestiture of non-core Advanced Rehabilitation Business in December 2024, simplifying operations and improving liquidity [sec_mda · as of 2025-05-06].
What to weigh
- Net sales from Surgical Solutions decreased $2.2M in Q2 2026 due to lower Ultrasonics volumes [sec_mda · as of 2026-08-05].
- U.S. Adjusted EBITDA declined 2.9% in Q3 2025, partly due to the divestiture of the Advanced Rehabilitation Business and unfavorable foreign currency movements [sec_mda · as of 2025-11-04].
- The strategic alternatives review process introduces uncertainty regarding the company's future structure and potential transactions [sec · filed 2026-08-05].
- Risks related to tariffs, trade barriers, and regulatory changes could impact operations and financial results [sec · filed 2026-04-22].
From the filings
Quoted directly from source documents.
Bioventus delivered its third consecutive year of strong results in 2025.
“2025 was another strong year for Bioventus, marked by continued execution against our strategy and tangible progress toward our long term growth objectives.”
SEC filings · April 22, 2026
Pain Treatments net sales increased $8.3M in Q2 2026, driven by volume and price growth.
“Net sales from Pain Treatments increased $8.3 million, reflecting 9.3% volume growth led by Durolane, and 3.6% price growth.”
SEC MD&A · August 5, 2026
The company is reviewing strategic alternatives with uncertain outcomes.
“the review of potential strategic alternatives; the potential outcomes, impact and timing thereof.”
SEC filings · August 5, 2026
Bioventus entered into a $300M term loan and $100M revolver in July 2025.
“On July 31, 2025, we entered into the 2025 Credit Agreement that provides for a $300.0 million term loan (the "2025 Term Loan") and a $100.0 million revolving credit facility (the "2025 Revolver").”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2024-05-07 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2024-08-06 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2024-11-05 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2025-03-11 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2025-05-06 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2025-08-06 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2025-11-04 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial performance updates.
- 2025-11-17 · PDUFA Date: assets - FDA PDUFA goal date — FDA decision on a product application; outcome could affect product pipeline.
Risks & what to watch (4)›
Key risks
- Strategic alternatives uncertainty — The review of strategic alternatives may lead to transactions that could dilute or change the company's structure [sec · filed 2026-08-05].
- Tariff and trade barrier risks — Unexpected changes in tariffs, trade barriers, and regulatory requirements could adversely affect operations [sec · filed 2026-04-22].
- Surgical Solutions revenue decline — Net sales from Surgical Solutions decreased $2.2M in Q2 2026 due to lower Ultrasonics volumes [sec_mda · as of 2026-08-05].
- Future capital needs — The company may need additional funding, which might not be available on acceptable terms [sec_mda · as of 2026-08-05].
What to watch
- Outcome of the strategic alternatives review process, which could include a sale, merger, or other transaction [sec · filed 2026-08-05].
- Continued performance of Pain Treatments, especially Durolane volume and price trends [sec_mda · as of 2026-08-05].
- Impact of tariffs and trade policies on international sales and supply chain [sec · filed 2026-04-22].
- Ability to maintain or grow Surgical Solutions and Restorative Therapies segments [sec_mda · as of 2026-08-05].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Bioventus Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bioventus Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.4 months
D/E 1.73 · 4% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
155
Total value held
$357.5M
| Holder | Shares | Value |
|---|---|---|
| essex woodlands management, inc. | 13,021,324 | $118.9M |
| vanguard capital management llc | 3,429,414 | $31.3M |
| blackrock, inc. | 3,133,541 | $28.6M |
| royce & associates lp | 1,541,282 | $14.1M |
| geode capital management, llc | 1,168,247 | $10.7M |
| state street corp | 988,367 | $9.0M |
| vanguard portfolio management llc | 973,004 | $8.9M |
| dimensional fund advisors lp | 873,138 | $8.0M |
| hillsdale investment management inc. | 671,139 | $6.1M |
| oberweis asset management inc/ | 628,114 | $5.7M |
Showing top 10 of 155 institutional holders of Bioventus Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.2%
- Days to cover
- 3.3
- Shares short
- 1,465,399
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bioventus Inc.?
Bioventus Inc. is a medical device company focused on surgical solutions, pain treatments, and restorative therapies, with a recent strategic review of alternatives and a strong financial position as of mid-2026.
Who is the CEO of Bioventus Inc.?
Mr. Robert E. Claypoole is the chief executive officer of Bioventus Inc. (BVS).
Where is Bioventus Inc. headquartered?
Bioventus Inc. (BVS) is headquartered in Durham, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.